All In Biotech

Drug Trial Radar · NCT07198087

A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

A Phase 1, Open-Label, Parallel-Group Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Oct 1, 2025

Primary completion

Apr 9, 2026

Study completion Apr 20, 2026

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to investigate the pharmacokinetics of tirabrutinib in participants with mild, moderate, and severe hepatic impairment compared to healthy participants

Conditions

  • Primary Central Nervous System Lymphoma (PCNSL)

Interventions

  • TirabrutinibDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic parameter of tirabrutinib: CmaxTime frame: 72 hour
  2. Pharmacokinetic parameter of tirabrutinib: TmaxTime frame: 72 hour
  3. Pharmacokinetic parameter of tirabrutinib: AUClastTime frame: 72 hour
  4. Pharmacokinetic parameter of tirabrutinib: AUCinfTime frame: 72 hour
  5. Pharmacokinetic parameter of tirabrutinib: T1/2Time frame: 72 hour
  6. Pharmacokinetic parameter of tirabrutinib: CL/FTime frame: 72 hour
  7. Pharmacokinetic parameter of tirabrutinib: Volume of distribution (Vd)Time frame: 72 hour
  8. Protein binding ratio of tirabrutinib in plasmaTime frame: 72 hour

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Liver Health

    Chandler, Arizona

  • Panax Clinical Research

    Miami Lakes, Florida

  • Orlando Clinical Research Center, Inc.

    Orlando, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.